(Total Views: 514)
Posted On: 06/03/2020 5:17:59 PM
Post# of 153822
That's a great point lorbas. So, within the Primary outcome they are measuring fever, myalgia, dyspnea and cough on a scale of 0-3. Each patient will be scored from 0-12 (higher being worse).
Do the four measurements provide more statistical strength? Or does the relatively small size create a situation where the p value could be high without a dramatic improvement from the leronlimab group?
And, further if we do in fact achieve p< .05 I would imagine its at the discretion of FDA whether to request a PH3. And would this be determined by the strength of the p value?
Do the four measurements provide more statistical strength? Or does the relatively small size create a situation where the p value could be high without a dramatic improvement from the leronlimab group?
And, further if we do in fact achieve p< .05 I would imagine its at the discretion of FDA whether to request a PH3. And would this be determined by the strength of the p value?
(0)
(0)
